文献速递肺外科心外重症与机械循环支持

依前列醇所致血小板减少对肺动脉高压肺移植的影响

Effect of epoprostenol-induced thrombocytopaenia on lung transplantation for pulmonary arterial hypertension.
PubMed 文献 · Eur J Cardiothorac Surg · 2024-01-01

本研究回顾性分析37例肺动脉高压肺移植患者,其中26例术前接受静脉依前列醇治疗(EPO组),11例未接受(no-EPO组)。EPO组术前血小板计数较低(中位数127 000 vs 176 000/μl),但术中失血量相似,术后血小板计数均显著升高,两组住院死亡率和3年生存率相似。结论认为接受依前列醇治疗的患者血小板计数相对较低,但肺移植后改善且预后良好。

要点

  • EPO组术前血小板中位数127 000/μl,低于no-EPO组的176 000/μl。
  • 两组术中失血量相似(EPO 2473 ml vs no-EPO 2615 ml)。
  • 术后1个月血小板显著升高,两组相似(EPO 298 000 vs no-EPO 284 000/μl)。

核心结论

  • 接受静脉依前列醇治疗的肺动脉高压患者血小板计数相对较低,肺移植后改善且移植后结局良好。

研究设计与样本

  • 回顾性分析2008年6月至2022年7月在本机构进行的37例肺动脉高压肺移植患者,其中特发性肺动脉高压26例、先天性心脏病相关肺动脉高压7例、肺静脉闭塞病3例、外周肺动脉狭窄1例。
  • 26例接受静脉依前列醇治疗(EPO组),11例未接受(no-EPO组)。

主要发现

  • 术前血小板计数中位数EPO组127 000/μl vs no-EPO组176 000/μl。
  • 术中失血量EPO组2473 ml vs no-EPO组2615 ml。
  • 术后1个月血小板计数显著升高,EPO组298 000/μl vs no-EPO组284 000/μl。
  • 住院死亡率EPO组3.9% vs no-EPO组18.2%,3年生存率EPO组91.4% vs no-EPO组80.8%,两组相似。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Preoperative intravenous epoprostenol therapy can cause thrombocytopaenia, which may increase the risk of perioperative bleeding during lung transplantation. This study aimed to determine whether lung transplantation can be safely performed in patients with epoprostenol-induced thrombocytopaenia. METHODS: From June 2008 to July 2022, we performed 37 lung transplants in patients with pulmonary arterial hypertension (PAH), including idiopathic PAH (n = 26), congenital heart disease-associated PAH (n = 7), pulmonary veno-occlusive disease (n = 3) and peripheral pulmonary artery stenosis (n = 1) at our institution. Of these, 26 patients received intravenous epoprostenol therapy (EPO group), whereas 11 patients were treated with no epoprostenol (no-EPO group). We retrospectively analysed the preoperative and postoperative platelet counts and post-transplant outcomes in each group. RESULTS: Preoperative platelet counts were relatively lower in the EPO group than in the no-EPO group (median EPO: 127 000 vs no-EPO: 176 000/μl). However, blood loss during surgery was similar between the 2 groups (EPO: 2473 ml vs no-EPO: 2615 ml). The platelet counts significantly increased over 1 month after surgery, and both groups showed similar platelet counts (EPO: 298 000 vs no-EPO: 284 000/μl). In-hospital mortality (EPO: 3.9% vs no-EPO: 18.2%) and the 3-year survival rate (EPO: 91.4% vs no-EPO: 80.8%) were similar between the 2 groups. CONCLUSIONS: Patients with PAH treated with intravenous epoprostenol showed relatively lower platelet counts, which improved after lung transplantation with good post-transplant outcomes.

来源:Eur J Cardiothorac Surg,查看原文。版权归原作者所有。

引用

  1. Date N, Nakajima D, Ikeda M, et al. Effect of epoprostenol-induced thrombocytopaenia on lung transplantation for pulmonary arterial hypertension. Eur J Cardiothorac Surg. 2024. PMID: 38539035. doi:10.1093/ejcts/ezae108

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。